5 results match your criteria: "Hospital-University Polyclinic of Bari[Affiliation]"
Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study.
Open Forum Infect Dis
June 2024
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Article Synopsis
- Meropenem-vaborbactam is a new treatment option for infections caused by KPC-producing Klebsiella pneumoniae, particularly those resistant to ceftazidime-avibactam.
- A study of 342 patients across 19 hospitals in Italy evaluated the outcomes of those treated with meropenem-vaborbactam, finding a 30-day mortality rate of 31.6%.
- The research identified risk factors for higher mortality, including septic shock, significant comorbidities, and delayed treatment, while the administration of the drug within 48 hours of infection onset was linked to better outcomes.
Predicting Factors of Worse Prognosis in COVID-19: Results from a Cross-sectional Study on 52 Inpatients Admitted to the Internal Medicine Department.
Endocr Metab Immune Disord Drug Targets
September 2024
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy.
Background: The initial phases of the COVID-19 pandemic posed a real need for clinicians to identify patients at risk of poor prognosis as soon as possible after hospital admission.
Aims: The study aimed to assess the role of baseline anamnestic information, clinical parameters, instrumental examination, and serum biomarkers in predicting adverse outcomes of COVID-19 in a hospital setting of Internal Medicine.
Methods: Fifty-two inpatients consecutively admitted to the Unit of Internal Medicine "Baccelli," Azienda Ospedaliero - Universitaria Policlinico of Bari (February 1 - May 31, 2021) due to confirmed COVID-19 were grouped into two categories based on the specific outcome: good prognosis (n=44), patients discharged at home after the acute phase of the infection; poor prognosis, a composite outcome of deaths and intensive care requirements (n=8).
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
Clin Infect Dis
November 2021
Department of Medical and Surgical Sciences, University of Bologna, IRCCS Pol. S. Orsola Bologna, Italy.
Article Synopsis
- Ceftazidime-avibactam (CAZ-AVI) has shown promise in treating infections caused by carbapenem-resistant bacteria, specifically Klebsiella pneumoniae, based on a review of patient data.
- In a study of 577 adults with severe infections, the overall 30-day mortality rate was 25%, with no significant difference in outcomes between those treated with CAZ-AVI alone and those using it in combination with other antibiotics.
- Factors like septic shock, neutropenia, and certain types of infections increased mortality risk, while longer infusion times of CAZ-AVI were associated with better outcomes, highlighting the need for further research on treatment protocols.
QTc Interval Prolongation and Life-Threatening Arrhythmias During Hospitalization in Patients With Coronavirus Disease 2019 (COVID-19): Results From a Multicenter Prospective Registry.
Clin Infect Dis
December 2021
Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Background: Prolonged QTc intervals and life-threatening arrhythmias (LTA) are potential drug-induced complications previously reported with antimalarials, antivirals, and antibiotics. Our objective was to evaluate the prevalence and predictors of QTc interval prolongation and incidences of LTA during hospitalization for coronavirus disease 2019 (COVID-19) among patients with normal admission QTc.
Methods: We enrolled 110 consecutive patients in a multicenter international registry.
Subcutaneous Human Dirofilariosis By D. Repens In South Italy: A Case Report.
New Microbiol
October 2019
Operative Unit of Infectious Diseases, Hospital-University Polyclinic of Bari, Italy.
Human dirofilariosis is a zoonosis caused by different Dirofilaria species: D. repens, D. immitis, D.
View Article and Find Full Text PDF